Tags

Type your tag names separated by a space and hit enter

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Abstract

Glucagon-like peptide-2 (GLP-2) is a potent intestinotrophic growth factor with therapeutic potential for the prevention or treatment of an expanding number of gastrointestinal diseases, including short bowel syndrome (SBS). Teduglutide, being developed by NPS Allelix and licensee Nycomed, is a protease-resistant analog of GLP-2 for the potential treatment of gastrointestinal disease. Teduglutide has prolonged biological activity compared with native GLP-2, and preclinical studies demonstrated significant intestinotrophic activity in models of SBS, experimental colitis and chemotherapy-induced intestinal mucositis. Patients with SBS rely on parenteral nutrition (PN) following bowel resection, and in a phase III clinical trial with teduglutide, > 20% reduction in PN was observed in patients with SBS receiving teduglutide. A phase II clinical trial for teduglutide in Crohn's disease observed remission rates of 55.6% in patients. At the time of publication, phase III clinical trials for SBS were ongoing, as were preclinical studies for chemotherapy-induced mucositis and pediatric indications. Teduglutide represents a novel, efficacious drug capable of increasing intestinal growth and improving intestinal function, and may change clinical management of intestinal disease and damage.

Authors+Show Affiliations

The University of Adelaide, Department of Medicine, Adelaide, South Australia 5005, Australia. roger.yazbek@adelaide.edu.au

Source

MeSH

Clinical Trials as Topic
Crohn Disease
Gastrointestinal Agents
Gastrointestinal Diseases
Glucagon-Like Peptide 2
Humans
Nausea
Peptides
Short Bowel Syndrome
Treatment Outcome
Vomiting

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21154171

Citation

Yazbeck, Roger. "Teduglutide, a Glucagon-like Peptide-2 Analog for the Treatment of Gastrointestinal Diseases, Including Short Bowel Syndrome." Current Opinion in Molecular Therapeutics, vol. 12, no. 6, 2010, pp. 798-809.
Yazbeck R. Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome. Curr Opin Mol Ther. 2010;12(6):798-809.
Yazbeck, R. (2010). Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome. Current Opinion in Molecular Therapeutics, 12(6), pp. 798-809.
Yazbeck R. Teduglutide, a Glucagon-like Peptide-2 Analog for the Treatment of Gastrointestinal Diseases, Including Short Bowel Syndrome. Curr Opin Mol Ther. 2010;12(6):798-809. PubMed PMID: 21154171.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome. A1 - Yazbeck,Roger, PY - 2010/12/15/entrez PY - 2010/12/15/pubmed PY - 2011/5/20/medline SP - 798 EP - 809 JF - Current opinion in molecular therapeutics JO - Curr. Opin. Mol. Ther. VL - 12 IS - 6 N2 - Glucagon-like peptide-2 (GLP-2) is a potent intestinotrophic growth factor with therapeutic potential for the prevention or treatment of an expanding number of gastrointestinal diseases, including short bowel syndrome (SBS). Teduglutide, being developed by NPS Allelix and licensee Nycomed, is a protease-resistant analog of GLP-2 for the potential treatment of gastrointestinal disease. Teduglutide has prolonged biological activity compared with native GLP-2, and preclinical studies demonstrated significant intestinotrophic activity in models of SBS, experimental colitis and chemotherapy-induced intestinal mucositis. Patients with SBS rely on parenteral nutrition (PN) following bowel resection, and in a phase III clinical trial with teduglutide, > 20% reduction in PN was observed in patients with SBS receiving teduglutide. A phase II clinical trial for teduglutide in Crohn's disease observed remission rates of 55.6% in patients. At the time of publication, phase III clinical trials for SBS were ongoing, as were preclinical studies for chemotherapy-induced mucositis and pediatric indications. Teduglutide represents a novel, efficacious drug capable of increasing intestinal growth and improving intestinal function, and may change clinical management of intestinal disease and damage. SN - 2040-3445 UR - https://www.unboundmedicine.com/medline/citation/21154171/Teduglutide,_a_glucagon-like_peptide-2_analog_for_the_treatment_of_gastrointestinal_diseases,_including_short_bowel_syndrome L2 - http://www.diseaseinfosearch.org/result/6543 DB - PRIME DP - Unbound Medicine ER -